Retatrutide: Triple GIP, GLP-1 and Glucagon Co-Agonist

While semaglutide (GLP-1R) and tirzepatide (GLP-1R + GIPR) have dominated metabolic peptide research headlines, a third generation has emerged. Retatrutide (formerly LY3437943, developed by Eli Lilly) is the first triple co-agonist investigated for simultaneous activation of all three incretin and glucagon receptors: GIP, GLP-1, and glucagon. This article covers what makes retatrutide mechanistically distinct and what current research data shows.

Triple Receptor Mechanism

Retatrutide activates three G protein-coupled receptors simultaneously:

• GLP-1R: Glucose-dependent insulin secretion, glucagon suppression, satiety signalling, slowed gastric emptying
• GIPR: Glucose-dependent insulin amplification, possible direct adipose tissue effects, central appetite regulation (additive with GLP-1R)
• Glucagon receptor (GCGR): Hepatic glucose output suppression, increased energy expenditure, potential direct lipolytic effects in adipose tissue

The inclusion of glucagon receptor agonism is the key differentiator. Glucagon classically raises blood glucose (counter-regulatory to insulin), but in the context of simultaneous GLP-1R and GIPR activation, the net metabolic effect is dramatically different: the hepatic glucose-lowering effects of GLP-1R and GIPR activation suppress any glucagon-induced glucose rise, while the GCGR's direct thermogenic and lipolytic effects on adipose tissue add a third dimension of metabolic activity not achievable with dual agonism alone.

Phase 2 Research Data

Two Phase 2 trials published in 2023 form the foundational retatrutide dataset. In the Phase 2 obesity trial (Jastreboff et al., New England Journal of Medicine, 2023), key findings included:

• 24.2% least-squares-mean body-weight reduction at 48 weeks in the highest-exposure arm (17.5% at the 24-week primary endpoint) — the highest weight-reduction figure reported for any incretin compound at the time
• An exposure-dependent response was reported across the four arms studied
• Adverse-event profile consistent with GLP-1 class effects (nausea, vomiting; primarily early and transient)

A separate Phase 2 type-2-diabetes trial (Rosenstock et al., The Lancet, 2023) reported roughly −2.0% HbA1c and about −17% body-weight change in the highest-exposure arm over 36 weeks (least-squares means).

The Phase 3 registrational programme — named TRIUMPH (TRIUMPH-1 through -5) — is ongoing; the 2023 Phase 2 studies pre-date and are separate from it. No head-to-head RCT against tirzepatide is yet published.

Why Retatrutide Research Is Significant

From a research perspective, retatrutide provides the most complete dissection of incretin and glucagon receptor biology achievable with a single compound. Researchers can use retatrutide to probe: What is the incremental contribution of GCGR to thermogenesis above GLP-1R + GIPR? How does triple receptor activation affect hepatic lipid metabolism beyond dual agonism? What is the ceiling of weight reduction achievable via receptor agonism alone?

These questions have implications beyond metabolic research — into fatty liver disease, MASH, cardiovascular risk, and potentially neurodegenerative models where metabolic dysregulation plays a contributing role.

Availability as a Research Compound

Retatrutide is available from Peptiko as a research-grade compound at ≥99% HPLC-MS purity. Given that most research peptide suppliers do not stock this compound — it represents a significant research catalogue advantage for early-stage laboratory investigation.